Sandbox Impetigo ammu: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
===Impetigo=== | ===Impetigo=== | ||
* Impetigo, adult | * Impetigo, adult<ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910 }} </ref><ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910 }} </ref> | ||
:* Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci) | :* Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci) | ||
::* '''Limited number of lesions''' | ::* '''Limited number of lesions''' | ||
Revision as of 14:28, 13 August 2015
Impetigo
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of post streptococcal glomerulonephritis
- Preferred regimen: Dicloxacillin 250 mg PO qid for 7 days OR Amoxicillin-Clavulanate 875/125 mg PO bid for 7 days OR Cephalexin 250 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300–400 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 1–2 double-strength tablets PO bid for 7 days
- Culture-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 250–500 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 250 mg PO qid for 7 days OR Clindamycin 300–400 mg PO qid for 7 days
- Methicillin-resistant Staphylococcus aureus
- Preferred regimen: Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300–450 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 1–2 double-strength tablets PO bid for 7 days
- Impetigo, pediatric
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of poststreptococcal glomerulonephritis
- Preferred regimen: Amoxicillin-Clavulanate 25 mg/kg/day of amoxicillin component PO bid for 7 days OR Cephalexin 25–50 mg/kg/day PO tid–qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Clindamycin 25–30 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 8–12 mg/kg/day PO bid for 7 days
- Culture-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 60,000–100,000 U/kg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 40 mg/kg/day PO tid–qid for 7 days OR Clindamycin 20 mg/kg/day PO tid for 7 days
- Methicillin-resistant Staphylococcus aureus
- Preferred regimen: Clindamycin 25–30 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 8–12 mg/kg/day PO bid for 7 days
References
- ↑ 1.0 1.1 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.